Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 5.5% – Here’s Why

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price dropped 5.5% during trading on Monday . The stock traded as low as $32.38 and last traded at $32.5860. 72,708 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 230,977 shares. The stock had previously closed at $34.50.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. Wall Street Zen upgraded Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Sensei Biotherapeutics in a report on Thursday, June 4th. JonesTrading assumed coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price objective on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $56.25.

Sensei Biotherapeutics Trading Up 0.3%

The firm has a market capitalization of $863.06 million, a price-to-earnings ratio of -0.24 and a beta of -0.28. The company’s 50-day simple moving average is $31.96.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, sell-side analysts predict that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current year.

Insider Activity

In related news, CFO Brian C. Stephenson bought 5,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was purchased at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the acquisition, the chief financial officer owned 46,688 shares in the company, valued at $1,097,168. This trade represents a 11.99% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased 19,884 shares of company stock valued at $482,056 over the last 90 days. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of Sensei Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new position in shares of Sensei Biotherapeutics in the 2nd quarter worth $307,000. Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares during the period. Bank of America Corp DE lifted its stake in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics during the 2nd quarter worth approximately $3,610,000. Finally, Stempoint Capital LP purchased a new position in Sensei Biotherapeutics in the first quarter valued at approximately $4,188,000. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.